Mycovia Pharmaceuticals

Mycovia Pharmaceuticals company information, Employees & Contact Information

Mycovia Pharmaceuticals was formed in 2018 following the acquisition of Viamet Pharmaceuticals by NovaQuest Capital Management. At Mycovia, we are passionate about developing breakthrough therapies in women’s health and dermatology. Our lead product candidate, VT-1161, is being developed as a treatment for recurrent vulvovaginal candidiasis (RVVC), a yeast infection that affects millions of women each year and often leads to distressing physical discomfort and a negative impact on psychological well-being. In studies to date, VT-1161 has demonstrated a high degree of potency against the organisms that cause RVVC. It may also have a lesser tendency to induce drug resistance and the variety of side effects that limit the use of currently available oral antifungal therapies. We are conducting global Phase 3 clinical trials in RVVC. VT-1161 has also been studied in onychomycosis, a fungal infection of the nail which affects approximately 35 million people in the United States and millions more around the globe. Onychomycosis can be a significant medical issue particularly for diabetics or other patients with compromised immune systems or poor circulation of the lower extremities.

Company Details

Employees
18
Founded
-
Address
4505 Emperor Blvd, Durham,north Carolina 27703,united States
Phone
919-467-8539
Email
in****@****via.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Durham, North Carolina
Looking for a particular Mycovia Pharmaceuticals employee's phone or email?

Mycovia Pharmaceuticals Questions

News

Mycovia Pharmaceuticals, Inc. Announces First Participant Enrolled in an Investigator-Initiated Phase 2 Study for Cryptococcal Meningitis - PR Newswire

Mycovia Pharmaceuticals, Inc. Announces First Participant Enrolled in an Investigator-Initiated Phase 2 Study for Cryptococcal Meningitis PR Newswire

Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd.'s Recognition for the Inclusion of VIVJOA® (Oteseconazole) Capsules in the Chinese National Reimbursement Drug List - PR Newswire

Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd.'s Recognition for the Inclusion of VIVJOA® (Oteseconazole) Capsules in the Chinese National Reimbursement Drug List PR Newswire

FDA Approves Mycovia Pharmaceuticals’ VIVJOA™ (oteseconazole), the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection) - Business Wire

FDA Approves Mycovia Pharmaceuticals’ VIVJOA™ (oteseconazole), the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection) Business Wire

First Participant Enrolled in Phase 2 Study for Investigational Antifungal For Cryptococcal Meningitis - Contagion Live

First Participant Enrolled in Phase 2 Study for Investigational Antifungal For Cryptococcal Meningitis Contagion Live

Vivjoa From Mycovia Pharmaceuticals, Inc - Pharmacy Times

Vivjoa From Mycovia Pharmaceuticals, Inc Pharmacy Times

FDA approves first drug for RVVC - Contemporary OB/GYN

FDA approves first drug for RVVC Contemporary OB/GYN

Mycovia Pharmaceuticals - The Pharma Letter

Mycovia Pharmaceuticals The Pharma Letter

Jiangsu Hengrui In-Licenses Treatment for Yeast Infection from Mycovia - NAI500

Jiangsu Hengrui In-Licenses Treatment for Yeast Infection from Mycovia NAI500

Mycovia Pharmaceuticals Announces Presentation of Results from Three Safety Studies Evaluating VIVJOA® (oteseconazole) in Subjects with Renal or Hepatic Impairment, and the Impact on QT Prolongation at the 2024 IDSOG Annual Meeting - PR Newswire

Mycovia Pharmaceuticals Announces Presentation of Results from Three Safety Studies Evaluating VIVJOA® (oteseconazole) in Subjects with Renal or Hepatic Impairment, and the Impact on QT Prolongation at the 2024 IDSOG Annual Meeting PR Newswire

Top Mycovia Pharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant